Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Axogen, Inc. Acquires BioCircuit Technologies, Inc.

PUBLIC · AXGNSep 10, 2026about 2 hours ago

Acquiring Company

Axogen

Acquired Company

BioCircuit Technologies

AlachuaAtlantaBiotechnologyHealth CareMedicalBiotechnology

Description

On September 9, 2026, Axogen, Inc. entered into a Merger Agreement with BioCircuit Technologies, Inc. Under the agreement, BioCircuit will merge into a subsidiary of Axogen and operate as a wholly owned subsidiary. The transaction is valued at $200.0 million in cash, subject to customary adjustments.

Company Information

Company

Axogen

Location

Alachua, Florida, United States

About

Weiler is the Executive Vice President, Chief Commercial and Growth Officer at Amwell (NYSE: AMWL). Weiler oversees the company’s growth strategy, driving strategic initiatives and leading business development, sales and account management, commercial enablement, marketing, and strategic and channel partnership teams. Prior to Amwell, Weiler served as Chief Consumer Officer at Optum, where she led consumerism across the enterprise. Preceding that, she was Chief Consumer Strategy Officer at UnitedHealth Group and the Chief Marketing and Experience Officer of Optum Health, leading marketing efforts for Optum Care and Optum’s Population Health Solutions, Complex Care Management, Medical Benefits Management, Behavioral Health, Prevention and Financial Services businesses. Weiler also served as Chief Marketing and Product Officer at Blue Cross and Blue Shield of Massachusetts, where she drove strategic growth and retention business objectives. Weiler spent her earlier career with multiple financial services organizations. She was Chief Marketing Officer of Fidelity Investments FAS business and held senior marketing leadership roles at BNY Mellon/Pershing and The Hartford. Weiler holds a B.A. from Bowdoin College and an M.A. in International Economics and Finance from Brandeis University. Axogen (AXGN) is the leading Company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products that are used across two primary application categories: scheduled, non-trauma procedures and emergent trauma procedures. Scheduled procedures are generally characterized as those where a patient is seeking relief from conditions caused by a nerve defect or surgical procedure. These procedures include providing sensation for women seeking breast reconstruction following a mastectomy, nerve reconstruction following the surgical removal of painful neuromas, oral and maxillofacial procedures, and nerve decompression. Emergent procedures are generally characterized as procedures resulting from injuries that initially present in an ER. These procedures are typically referred to and completed by a specialist either immediately or within a few days following the initial injury. Axogen’s product portfolio includes Avance® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector®, a porcine submucosa ECM coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector®, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard HA+ Nerve Protector™, a porcine submucosa ECM base layer coated with a proprietary hyaluronate-alginate gel, a next-generation technology designed to provide short- and long-term protection for peripheral nerve injuries; and Axoguard Nerve Cap®, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

Don't miss Axogen's next move

Get an email the moment Axogen makes an acquisition, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Michael
Likely contact at this company
••••••••@••••••••

See Michael's verified email →

Craig
Likely contact at this company
••••••••@••••••••

See Craig's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for Axogen's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired BioCircuit Technologies?

BioCircuit Technologies was acquired by Axogen, based in Alachua. The deal was reported on September 10, 2026. Weiler is the Executive Vice President, Chief Commercial and Growth Officer at Amwell (NYSE: AMWL). Axogen is publicly traded (AXGN) and operates in Biotechnology.

When did Axogen acquire BioCircuit Technologies?

Axogen's acquisition of BioCircuit Technologies was reported on September 10, 2026. On September 9, 2026, Axogen, Inc. entered into a Merger Agreement with BioCircuit Technologies, Inc. Under the agreement, BioCircuit will merge into a subsidiary of Axogen and operate as a wholly owned subsidiary. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does BioCircuit Technologies do?

Based in Atlanta, GA, BioCircuit Technologies develops and commercializes medical devices for tissue repair and neuromodulation. It is privately held, operating in Biotechnology, and is based in Atlanta.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.